HEPATOCELLULAR CANCER

This early-phase study tests a new treatment that takes a person's own immune cells, modifies them in a lab to better recognize and attack cancer cells, and then returns them to the patient. It is for adults with advanced solid tumors that express a protein called GPC3, such as l…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if…

This early-phase study tests an investigational drug called ABBV-324 in adults with liver cancer (hepatocellular cancer) or a type of lung cancer (squamous-cell non-small cell lung cancer). The main goals are to check safety, find the right dose, and see if the drug shrinks tumor…

This study tests a new medicine, PF-08634404, given alone or with another drug (ipilimumab) for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and shrinks tumors. About 138 participants will receive the drug throug…

This early-phase study tests whether combining targeted radiation beads (SIRT) with two immunotherapy drugs (tremelimumab and durvalumab) is safe and effective before liver cancer surgery. About 20 adults with resectable liver cancer will receive the treatment and then undergo su…

This study tests a personalized vaccine made from a patient's own immune cells, combined with an immunotherapy drug (nivolumab), after surgery to remove liver cancer or colorectal cancer that spread to the liver. The goal is to see if this treatment can prevent the cancer from re…

This study collects blood, urine, and bone marrow samples from 320 people with solid cancers (like lung, colon, or pancreatic cancer) and from those undergoing lung cancer screening. The goal is to detect tiny bits of tumor cells and DNA in these fluids to learn how cancer spread…